These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1276 related articles for article (PubMed ID: 8331230)

  • 1. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.
    Hoh CK; Hawkins RA; Glaspy JA; Dahlbom M; Tse NY; Hoffman EJ; Schiepers C; Choi Y; Rege S; Nitzsche E
    J Comput Assist Tomogr; 1993; 17(4):582-9. PubMed ID: 8331230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study.
    Inoue T; Koyama K; Oriuchi N; Alyafei S; Yuan Z; Suzuki H; Takeuchi K; Tomaru Y; Tomiyoshi K; Aoki J; Endo K
    Radiology; 2001 Jul; 220(1):54-62. PubMed ID: 11425972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
    Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose.
    Rege SD; Hoh CK; Glaspy JA; Aberle DR; Dahlbom M; Razavi MK; Phelps ME; Hawkins RA
    Cancer; 1993 Jul; 72(1):82-90. PubMed ID: 8389668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
    Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
    J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
    J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis.
    Dewan NA; Reeb SD; Gupta NC; Gobar LS; Scott WJ
    Chest; 1995 Aug; 108(2):441-6. PubMed ID: 7634881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma.
    Gritters LS; Francis IR; Zasadny KR; Wahl RL
    J Nucl Med; 1993 Sep; 34(9):1420-7. PubMed ID: 8355058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cancer detection with whole-body FDG PET images without attenuation correction].
    Yasuda S; Ide M; Takagi S; Shohtsu A; Mitomi T; Kobayashi S; Suzuki Y
    Kaku Igaku; 1996 Apr; 33(4):367-73. PubMed ID: 8683875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
    Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
    Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma.
    Karlan BY; Hawkins R; Hoh C; Lee M; Tse N; Cane P; Glaspy J
    Gynecol Oncol; 1993 Nov; 51(2):175-81. PubMed ID: 8276290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
    Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
    J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional 2-[18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung.
    Miyauchi T; Wahl RL
    Eur J Nucl Med; 1996 May; 23(5):517-23. PubMed ID: 8698055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.
    Shulkin BL; Mitchell DS; Ungar DR; Prakash D; Dole MG; Castle VP; Hernandez RJ; Koeppe RA; Hutchinson RJ
    Radiology; 1995 Feb; 194(2):495-500. PubMed ID: 7824731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
    Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of chest masses by FDG positron emission tomography.
    Hübner KF; Buonocore E; Singh SK; Gould HR; Cotten DW
    Clin Nucl Med; 1995 Apr; 20(4):293-8. PubMed ID: 7788982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
    Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
    J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
    Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
    J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-body [18F]FDG PET in the management of metastatic brain tumours.
    Kim DG; Kim CY; Paek SH; Lee DS; Chung JK; Jung HW; Cho BK
    Acta Neurochir (Wien); 1998; 140(7):665-73; discussion 673-4. PubMed ID: 9781280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.